COMENTIS
CoMentis is a biotech company focused on the research and development of small molecule drugs to treat neurovascular diseases such as Alzheimer's disease (AD), age-related macular degeneration (AMD) and other cognitive disorders. Originally founded in 2004 as Athenagen, Inc., the company was re-named CoMentis following its August 2006 merger with Zapaq, Inc., which created a leading neurovascular disease franchise.
COMENTIS
Industry:
Biotechnology Health Care Medical
Founded:
2004-01-01
Address:
South San Francisco, California, United States
Country:
United States
Total Employee:
11+
Status:
Closed
Total Funding:
107.5 M USD
Founder
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2006-07-10 | Zapaq | Zapaq acquired by CoMentis | N/A |
Investors List
Index Ventures
Index Ventures investment in Series D - CoMentis
Clarus Ventures
Clarus Ventures investment in Series D - CoMentis
Muralitharan Kengatharan
Muralitharan Kengatharan investment in Series D - CoMentis
Scott Harkonen
Scott Harkonen investment in Series D - CoMentis
Astellas Pharma
Astellas Pharma investment in Series D - CoMentis
John P. Cooke
John P. Cooke investment in Series D - CoMentis
Claris Lifesciences
Claris Lifesciences investment in Series D - CoMentis
Charter Life Sciences
Charter Life Sciences investment in Series D - CoMentis
John Donovan
John Donovan investment in Series D - CoMentis
Robin J. Cook
Robin J. Cook investment in Series D - CoMentis